Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetic Neuropathy

In brief

The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo.

Key facts

Study ID
NCT00568035
Run by
Quigley Pharma, Inc.
People needed
140
Starts
2006-12-01
Expected to finish
2008-11-01
Last updated by the study team
2009-01-08

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.